iShares Genomics Immunology and Healthcare Index ETF CADTSX:XDNA
- LAST PRICE31.45
- TODAY'S CHANGE (%)0.64 (2.08%)
- Bid / Lots31.21/ 1
- Ask / Lots31.42/ 1
- Open / Previous Close31.45 / 30.81
- Day Range
- 52 Week Range
- Volume400
- Overall Morningstar RatingNot Ratedout of funds
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XDNA |
|---|---|---|
| 02:11 ET | 400 | 31.45 |
| US Equity | 69.6% |
|---|---|
| Int'l Equity | 28.8% |
| CDN Equity | 1.1% |
| Cash | 0.5% |
| Fixed Income | 0 |
| Other | 0 |
| Healthcare | 99.6% |
|---|---|
| Basic Mat. | 0 |
| Communication Services | 0 |
| Consumer Cyclical | 0 |
| Consumer Defensive | 0 |
| Energy | 0 |
| Financial Serv.s | 0 |
| Industrials | 0 |
| Real Estate | 0 |
| Technology | 0 |
| Utilities | 0 |
| United States | 70.0% |
|---|---|
| Europe | 8.1% |
| Asia/Oceania | 5.8% |
| Canada | 1.1% |
| Africa | 0 |
| Latin America | 0 |
| Company Name sortable | Position sortable | Allocation sortable | Allocation sortable1 Month Change | Market Value sortable |
|---|---|---|---|---|
Sarepta Therapeutics Inc | Long | 5.4% | 0.00% | $270.8K |
Moderna Inc | Long | 4.7% | 0.00% | $235.9K |
Revolution Medicines Inc Ordinary Shares | Long | 4.6% | 0.00% | $232.6K |
Merck & Co Inc | Long | 4.5% | 0.00% | $225.3K |
GSK PLC | Long | 4.2% | 0.00% | $210.3K |
Regeneron Pharmaceuticals Inc | Long | 4.1% | 0.00% | $208.4K |
Exelixis Inc | Long | 3.8% | 0.00% | $191.2K |
Sanofi SA | Long | 3.7% | 0.00% | $186.8K |
Incyte Corp | Long | 3.7% | 0.00% | $186.3K |
Iovance Biotherapeutics Inc | Long | 3.6% | 0.00% | $179.3K |
Reports
Morningstar Ratings
| Time Horizon | Star Rating |
|---|---|
| Overall Rating | Not Rated |
| 3 Year Rating | Not Rated |
| 5 Year Rating | Not Rated |
| 10 Year Rating | Not Rated |
Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.
Style Box is calculated only using the long position holdings of the portfolio.
Best Fit Index | --- |
|---|---|
Category | Sector Equity |
Sponsor | BlackRock Canada |
Inception | April 26, 2022 |
XDNA seeks to provide long-term capital growth by replicating, to the extent possible, the performance, net of expenses, of an Index selected at the discretion of BlackRock Canada that is composed of securities of issuers that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering, as determinedby the Index Provider. XDNA currently seeks to replicate the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. Under normal market conditions, XDNA will primarily invest in securities of one or more iShares ETFs and/or international equity securities.
| Total Net Assets | $5.0M |
|---|---|
| Shares Out. | 150.0K |
| Net Asset Value (NAV) | $31.33 |
| Prem/Discount to NAV | 0.38% |
| P/E Ratio | --- |
| Dividend Yield | --- |
| Dividend per Share | --- |
| Ex-Dividend Date | --- |
| Dividend Payment Date | --- |
| Beta | --- |
| Morningstar Investment Style | Sector Equity |
| Equity Style | Mid Cap Growth |
| Credit Quality / Duration | --- |
| Actual Management Fee | 0.39% |
|---|---|
| Actual Mgmt. Expense Ratio (MER) | 0.44% |